Weighted Average Number of Shares Outstanding, Basic of NEKTAR THERAPEUTICS from 30 Sep 2013 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
NEKTAR THERAPEUTICS quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 30 Sep 2013 to 31 Dec 2025.
  • NEKTAR THERAPEUTICS Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 16,870,930, a 23% increase year-over-year.
  • NEKTAR THERAPEUTICS annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 16,870,930, a 23% increase from 2024.
  • NEKTAR THERAPEUTICS annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 13,710,775, a 93% decline from 2023.
  • NEKTAR THERAPEUTICS annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 190,001,000, a 1.5% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

NEKTAR THERAPEUTICS Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 16,870,930 +3,160,155 +23% 01 Oct 2025 31 Dec 2025 10-K 13 Mar 2026 2025 FY
Q3 2025 18,946,559 +4,996,708 +36% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 14,087,307 +165,929 +1.2% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 210,924,000 +16,178,000 +8.3% 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 13,710,775 -176,290,225 -93% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2026 2025 FY
Q3 2024 13,949,851 -176,456,149 -93% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025 2025 Q3
Q2 2024 13,921,378 -175,734,622 -93% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 194,746,000 +5,871,000 +3.1% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q4 2023 190,001,000 +2,863,000 +1.5% 01 Oct 2023 31 Dec 2023 10-K 14 Mar 2025 2024 FY
Q3 2023 190,406,000 +2,765,000 +1.5% 01 Jul 2023 30 Sep 2023 10-Q 08 Nov 2024 2024 Q3
Q2 2023 189,656,000 +2,856,000 +1.5% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 188,875,000 +3,027,000 +1.6% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 187,138,000 +3,840,000 +2.1% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
Q3 2022 187,641,000 +3,531,000 +1.9% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 186,800,000 +4,102,000 +2.2% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 185,848,000 +4,478,000 +2.5% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 183,298,000 01 Oct 2021 31 Dec 2021 10-K 05 Mar 2024 2023 FY
Q3 2021 184,110,000 +5,020,000 +2.8% 01 Jul 2021 30 Sep 2021 10-Q 04 Nov 2022 2022 Q3
Q2 2021 182,698,000 +4,371,000 +2.5% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022 2022 Q2
Q1 2021 181,370,000 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q3 2020 179,090,000 +3,688,000 +2.1% 01 Jul 2020 30 Sep 2020 10-Q 05 Nov 2021 2021 Q3
Q2 2020 178,327,000 +3,778,000 +2.2% 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021 2021 Q2
Q3 2019 175,402,000 +2,704,000 +1.6% 01 Jul 2019 30 Sep 2019 10-Q 07 Nov 2019 2019 Q3
Q2 2019 174,549,000 +3,171,000 +1.8% 01 Apr 2019 30 Jun 2019 10-Q 09 Aug 2019 2019 Q2
Q3 2018 172,698,000 +16,287,000 +10% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 171,378,000 +16,026,000 +10% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2019 Q2
Q3 2017 156,411,000 +19,317,000 +14% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 155,352,000 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q3 2016 137,094,000 +4,463,000 +3.4% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q1 2016 135,793,000 +4,434,000 +3.4% 01 Jan 2016 31 Mar 2016 10-Q 04 May 2016 2016 Q1
Q3 2015 132,631,000 +5,127,000 +4% 01 Jul 2015 30 Sep 2015 10-Q 06 Nov 2015 2015 Q3
Q1 2015 131,359,000 +7,816,000 +6.3% 01 Jan 2015 31 Mar 2015 10-Q 04 May 2016 2016 Q1
Q3 2014 127,504,000 +11,692,000 +10% 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015 2015 Q3
Q1 2014 123,543,000 01 Jan 2014 31 Mar 2014 10-Q 01 May 2015 2015 Q1
Q3 2013 115,812,000 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014 2014 Q3

NEKTAR THERAPEUTICS Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 16,870,930 +3,160,155 +23% 01 Jan 2025 31 Dec 2025 10-K 13 Mar 2026 2025 FY
2024 13,710,775 -176,290,225 -93% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2026 2025 FY
2023 190,001,000 +2,863,000 +1.5% 01 Jan 2023 31 Dec 2023 10-K 14 Mar 2025 2024 FY
2022 187,138,000 +3,840,000 +2.1% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
2021 183,298,000 +4,717,000 +2.6% 01 Jan 2021 31 Dec 2021 10-K 05 Mar 2024 2023 FY
2020 178,581,000 +3,588,000 +2% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 174,993,000 +5,393,000 +3.2% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 169,600,000 +13,647,000 +8.8% 01 Jan 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
2017 155,953,000 +16,357,000 +12% 01 Jan 2017 31 Dec 2017 10-K 28 Feb 2020 2019 FY
2016 139,596,000 01 Jan 2016 31 Dec 2016 10-K 01 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.